Trial Profile
A Phase I/Ib Study of Lenvatinib and Cetuximab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Oct 2022
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Lenvatinib (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Mouth neoplasm; Nasopharyngeal cancer; Oropharyngeal cancer; Skin cancer; Squamous cell cancer
- Focus Adverse reactions
- 13 Oct 2022 Status changed from active, no longer recruiting to completed.
- 18 Oct 2021 Status changed from recruiting to active, no longer recruiting.
- 01 Feb 2021 Planned End Date changed from 1 Apr 2021 to 1 Apr 2023.